Ctrl

K

Talazoparib

Class
Targeted therapy
Subclass
PARP inhibitors
Substance name
Talazoparib
Brand names
Talzenna®
Common formulations
Capsule
Dosage and administration
Adults patients
Treatment of breast cancer in postmenopausal females with PIK3CA mutation without HER2 mutation • Advanced or metastatic, HR-positive
•
1 mg PO daily until disease progression or unacceptable toxicity occurs
Indications for use
Labeled indications
Adults
•
Treatment of breast cancer in females (advanced or metastatic)
•
Treatment of breast cancer in postmenopausal females with PIK3CA mutation without HER2 mutation (advanced or metastatic, HR-positive)
Pregnancy and breastfeeding
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Alopecia, anemia, bone fracture, ↓ blood neutrophil count, ↓ platelet count, abdominal pain, diarrhea, dizziness, fatigue, headache, loss of appetite, nausea, vomiting
Common 1-10%
•
Change in taste, indigestion, stomatitis, venous thromboembolism
Uncommon < 1%
•
Febrile neutropenia
Unknown frequency
•
Acute myeloid leukemia, myelodysplastic syndrome, myelosuppression
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource